Comparison of the Effects of Telbivudine and Entecavir Treatment on Estimated Glomerular Filtration Rate in Patients with Chronic Hepatitis B.
- Author:
Sangheun LEE
1
;
Jun Yong PARK
;
Kijun SONG
;
Do Young KIM
;
Beom Kyung KIM
;
Seung Up KIM
;
Hye Jin KU
;
Kwang Hyub HAN
;
Sang Hoon AHN
Author Information
- Publication Type:Comparative Study ; Original Article ; Research Support, Non-U.S. Gov't
- Keywords: Telbivudine; Entecavir; Estimated glomerular filtration rate
- MeSH: Adult; Antiviral Agents/*administration & dosage; Diabetes Complications; Diabetes Mellitus; Drug Administration Schedule; Female; Fibrosis/complications; Glomerular Filtration Rate/*drug effects; Guanine/administration & dosage/*analogs & derivatives; Hepatitis B, Chronic/complications/*drug therapy/physiopathology; Humans; Hypertension/complications; Linear Models; Male; Middle Aged; Thymidine/administration & dosage/*analogs & derivatives; Time Factors; Treatment Outcome
- From:Gut and Liver 2015;9(6):776-783
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND/AIMS: The aim of this study was to evaluate the estimated glomerular filtration rate (eGFR) during telbivudine (LdT) versus entecavir (ETV) treatment in chronic hepatitis B (CHB) patients with underlying comorbidities such as diabetes mellitus (DM), hypertension, and cirrhosis. METHODS: From 2010 to 2012, 116 CHB patients treated with LdT and 578 treated with ETV were compared in this real-practice cohort. The mean changes in eGFR (Modification of Diet in Renal Disease [MDRD] formula) from baseline to months 6, 12, and 18 were analyzed using a linear mixed model. RESULTS: In LdT-treated patients, the mean eGFR increased by 7.6% at month 18 compared with the eGFR at baseline (MDRD formula in mL/min/1.73 m2). However, in ETV-treated patients, the mean eGFR decreased by 4.1% at month 18 compared with the eGFR at baseline. In the LdT-treated patients with DM, hypertension, cirrhosis or low eGFR <90 mL/min/1.73 m2, the mean eGFR showed a steady improvement, whereas the mean eGFR was reduced in the same subgroups of ETV-treated patients. CONCLUSIONS: The eGFR gradually increased over time during LdT treatment, especially in patients with mild abnormal eGFR at baseline, and in those with DM, hypertension, and cirrhosis, whereas a reduction in eGFR was seen with ETV treatment.
